Target organ damage

Epigenetic age acceleration

Model 1

Model 2

Model 3


β

P

β

P

β

P


eGFR (n = 1389)

IEAA

−0.082

0.444

−0.042

0.694

−0.035

0.745

EEAA

0.119

0.180

0.095

0.284

0.089

0.320

UACR^{a} (n = 1390)

IEAA

0.023

0.004

0.017

0.036

8.9E−3

0.246

EEAA

0.010

0.187

7.2E3

0.287

1.5E3

0.826

RWT (n = 1352)

IEAA

6.2E−4

0.022

5.4E4

0.041

4.5E4

0.089

EEAA

3.4E5

0.886

4.8E5

0.836

−1.2E4

0.598

LVMI (n = 1346)

IEAA

0.163

0.007

0.110

0.054

0.062

0.260

EEAA

0.131

0.005

0.119

0.009

0.093

0.029

ABI (n = 1359)

IEAA

−2.1E3

0.014

−1.9E3

0.028

−1.6E3

0.057

EEAA

−1.2E3

0.075

−1.0E3

0.117

−8.4E−4

0.196

WMH^{a} (n = 758)

IEAA

4.2e3

0.333

−5.4e3

0.213

−7.8e3

0.075

EEAA

6.8e3

0.068

7.0e3

0.053

5.7e3

0.109

 Abbreviations: IEAA Intrinsic epigenetic age acceleration, EEAA Extrinsic epigenetic age acceleration, eGFR Estimated glomerular filtration rate, UACR Urinary albumin to creatinine ratio, RWT Relative wall thickness, LVMI Left ventricular mass index, ABI Anklebrachial index, WMH White matter hyperintensity
 Model 1: Target organ damage = epigenetic age acceleration + chronological age + sex + time between methylation and target organ damage measure
 Model 2: Target organ damage = Model 1 covariates + SBP + DBP + antihypertensive medication
 Model 3: Target organ damage = Model 2 covariates + smoking + diabetes + BMI
 Model 3 for RWT and LVM also includes microalbuminuria and macroalbuminuria
 All models for WMH also include total intracranial volume (TIV)
 ^{a}Variables were natural log transformed prior to analysis
 Bold values correspond to beta values and pvalues, where p < 0.05